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Introduction: Human epidermal growth factor receptor HER3 has been implicated in promoting the aggressiveness
and metastatic potential of breast cancer. Upregulation of HER3 has been found to be a major mechanism underlying
drug resistance to EGFR and HER2 tyrosine kinase inhibitors and to endocrine therapy in the treatment of breast
cancer. Thus, agents that reduce HER3 expression at the plasma membrane may synergize with current therapies and
offer a novel therapeutic strategy to improve treatment.
Methods: We devised an image-based screening platform using membrane localized HER3-YFP to identify small
molecules that promote HER3 internalization and degradation. In vitro and in vivo tumor models were used to
characterize the signaling effects of perhexiline, an anti-anginal drug, identified by the screening platform.
Results: We found perhexiline, an anti-anginal drug, selectively internalized HER3, decreased HER3 expression, and
subsequently inhibited signaling downstream of HER3. Consistent with these results, perhexiline inhibited breast
cancer cell proliferation in vitro and tumor growth in vivo.
Conclusions: This is the first demonstration that HER3 can be targeted with small molecules by eliminating it
from the cell membrane. The novel approach used here led to the discovery that perhexiline ablates HER3
expression, and offers an opportunity to identify HER3 ablation modulators as innovative therapeutics to improve
survival in breast cancer patients.Introduction
Human epidermal growth factor receptor 3 (HER3) is a
single membrane-spanning receptor that exerts its func-
tion through heterodimerization with other HER family
receptors [1-3]. Activation of HER3-containing heterodi-
mers leads to HER3 phosphorylation and subsequent
activation of signaling pathways, including phos-
phatidylinositol 3-kinase (PI3K)/Akt and RAF/MEK/
extracellular signal-regulated protein kinase (ERK) path-
ways, that drive tumor cell proliferation and promote sur-
vival [2,4]. Increasing evidence has identified HER3 as one
of the most potent oncogenic factors in promoting breast
cancer tumorigenesis [5]. In animal models of breast* Correspondence: kim.lyerly@dm.duke.edu; w.chen@duke.edu
†Equal contributors
2Duke Comprehensive Cancer Center, Department of Surgery, Duke
University Medical Center, 200 Trent Drive, Durham, NC 27710, USA
1Department of Medicine, Duke University Medical Center, 595 Lasalle street,
Durham, NC 27710, USA
Full list of author information is available at the end of the article
© 2015 Ren et al.; licensee BioMed Central. Th
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.cancer driven by HER2, HER3 expression and phosphoryl-
ation are upregulated [6,7]. Knockout of HER3 impairs the
ability of HER2 to induce tumor formation in mouse
mammary tumor virus-HER2 (MMTV-HER2)-driven
mouse models [8]. In addition, overexpression of HER3
has been shown to significantly enhance the invasiveness
of breast cancer cells. Specifically, HER3 promotes inva-
sion and metastasis through its ability to activate the PI3K
pathway [9]. The clinical impact of HER3 is indicated by
the observation that increased HER3 expression and the
detection HER2/HER3 dimers have prognostic signifi-
cance in breast cancer [10,11].
Therapies targeting epidermal growth factor receptor
(EGFR) and HER2 have been extensively developed. Un-
fortunately, clinical efficacy is not satisfactory as drug
resistance reduces durable responses. Upregulation of
HER3 has been found as one of the major mechanisms
underlying drug resistance to EGFR and HER2 tyro-
sine kinase inhibitors (for example lapatinib, gefitinib,
erlotinib) and to endocrine therapy in the treatmentis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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that the expression of HER3 ligand heregulin (HRG) as
well as activation of HER3 signaling is involved in resist-
ance to anti-estrogen therapies in vitro and in vivo [15-17].
It has been suggested that effective therapies against HER2
require simultaneous targeting of HER3 [18]. Thus,
mounting evidence highlights the importance of targeting
HER3 to decrease breast cancer mortality [3].
In this report, we engineered an image-based screening
platform using membrane localized HER3-yellow fluores-
cent protein (YFP) to identify small molecules that promote
HER3 internalization and degradation. Using this platform,
we screened a library of Food and Drug Administration
(FDA) and foreign regulatory agency-approved drugs, and
identified that perhexiline, an anti-anginal drug that inhibits
mitochondrial carnitine palmitoyltransferase I (CPT-1) [19],
promotes HER3 internalization and downregulation, in-
hibits signaling downstream of HER3, and inhibits cancer
cell proliferation in vitro and in vivo.
Materials and methods
Reagents and antibodies
Perhexiline maleate salt was purchased from Sigma-
Aldrich (St. Louis, MO, USA). Neuregulin was pur-
chased from R&D Systems (Minneapolis, MN, USA).
The following antibodies were purchased from Santa
Cruz Biotechnology (Dallas, TX, USA): HER2 (3B5),
HER3 (C-17), and ubiquitin. The pAkt (Ser473), pERK1/2,
total EGFR, and Alexa Fluor™ 488 Conjugate Flag anti-
bodies were purchased from Cell Signaling (Beverly,
MA, USA). The antibodies were used at a 1:500 dilu-
tion in Western blotting. LysoTracker™ Red DND-99
was purchased from Invitrogen (Grand Island, NY, USA).
Cell culture
HEK293 and U2OS cells were cultured in Minimum
Essential Medium (MEM), SK-BR-3 cells were cultured
in McCoy’s 5A medium, and MDA-MB-468 cells were
cultured in Leibovitz’s L-15 medium. AU565 and BT474
cells were cultured in RPMI-1640 medium. All media
were supplemented with 10% fetal bovine serum (FBS,
Atlanta Biologicals, Lawrenceville, GA, USA), 200 U/ml
penicillin, and 50 ng/ml streptomycin (Invitrogen, Grand
Island, NY, USA). Cells were grown at 37°C in 5% CO2
except for the MDA-MB-468 cells that were grown at
37°C without CO2. All cell lines were purchased from
American Type Culture Collection (Manassas, VA, USA).
Expression constructs
The cDNA clone of human HER3 (pCMV-sport6-ERBB3,
IMAGE: 6147464) was obtained from the Mammalian
Gene Collection (MGC) through Open Biosystems
(GE Dharmacon, Lafayette, CO, USA). To generate the
C-terminal YFP-tagged HER3 (HER3-YFP), the codingregion of HER3 was amplified using polymerase chain re-
action (PCR) and subcloned in-frame into pcDNA3.1-
mYFP vector (a gift from Roger Y Tsien, University of
California at San Diego, USA). The primers used for PCR
amplification were 5′-GGGGTACCGGAGTCATGAG
GGCGAACGACGCTC −3′ and 5′-ATAAGAATGCGG
CCGCGTTCTCTGGGCATTAGCCTTGGG −3′, and
the HER3 fragment was cloned into the Kpn I and Not I
sites on the vector. In order to delete the nuclear
localization sequence (NLS2, ‘RRRR’) in HER3, site-
directed mutagenesis experiments were performed using
HER3-YFP as the template, and the primers used were:
5′-GAGTATGAATACATGAACCACAGTCCACCTCA
TCCC −3′ and 5′-GGGATGAGGTGGACTGTGGTT
CATGTATTCATACTC −3′. To generate the Flag-tagged
HER3ΔNLS2 construct, the coding sequence was ampli-
fied by PCR (primers used were: 5′-GGGGTACC
GAGGGCGAACGACGCTCTG-3′and 5′-GCTCTAGA
TTACGTTCTCTGGGCATTAGC-3′) and subcloned into
the Kpn I and Xba I sites on the pFlag-CMV3 vector
(Sigma-Aldrich, St Louis, MO, USA). All constructs were
verified by sequencing.
Imaging-based primary screening assay
Primary screening assays were performed as previously
described [20,21]. Briefly, U2OS cells stably expressing
HER3ΔNLS2-YFP were treated with compounds from a
library containing approximately 1,200 FDA and foreign
regulatory agency-approved drugs and drug-like tool
compounds (Prestwick Chemical Illkirch-Graffenstaden,
France). Cells were incubated with each compound for
6 hours at 37°C prior to fixation in phosphate-buffered
saline (PBS) containing 4% paraformaldehyde and
0.002% of the fluorescent nuclear stain DRAQ5. Plates
were stored at 4°C until analysis on an ImageXpress
Ultra high-throughput imaging system (Molecular
Devices, Sunnyvale, CA, USA) equipped with a 488 nm
argon laser for imaging GFP and a 568 nm krypton laser
for imaging DRAQ5. All imaging data were verified by vis-
ual inspection and a Z′ factor of 0.44 was calculated for
the robustness of the assay.
Immunofluorescence staining and imaging analysis
U2OS cells stably expressing HER3ΔNLS2-YFP plated
on 35-mm, poly-D-lysine-coated, glass-bottom micro-
well dishes (MatTek Cultureware, Ashland, MA, USA)
were treated with dimethyl sulfoxide (DMSO) or per-
hexiline for the indicated time at 37°C and followed by
fixation with 4% paraformaldehyde. HEK293 cells grown
in microwell dishes were transfected (Fugene6; Roche
Diagnostics Corp., Indianapolis, IN, USA) with Flag-
HER3ΔNLS2, and 24 hours post-transfection cells were
incubated with Alexa Fluor™ 488 Conjugate Flag anti-
body in culture medium on ice for 30 minutes. After
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with perhexiline or DMSO in culture medium at 37°C
for 1 hour followed by fixation. To detect endogenous
HER3 receptors, MDA-MB-468 cells were allowed to
grow for 24 hours and then treated with DMSO or per-
hexiline for the indicated time at 37°C before fixation in
4% paraformaldehyde. Fixed cells were permeabilized
and blocked in blocking buffer (5% bovine serum albu-
min (BSA) with 0.2% saponin in PBS) for 20 minutes at
room temperature and washed in PBS. Where indicated,
cells were incubated with HER3 antibody in blocking
buffer for 1 hour at room temperature and subsequently
incubated with the Alexa Fluor™ 488-conjugated goat
anti-rabbit secondary antibody (Invitrogen, Grand Island,
NY, USA) in blocking buffer for 1 hour at room
temperature. The slides were mounted in mounting
medium (Vector Laboratories, Inc., Burlingame, CA,
USA) and examined using a LSM 510-Meta confocal
microscope (Carl Zeiss, Thornwood, NY, USA) equipped
with 40× and 100× apo chromat objectives. YFP was
excited using a 488-nm argon laser line. Images were
processed using the LSM software Image Browser (Carl
Zeiss, Thornwood, NY, USA).
Assay of HER3 degradation and ubiquitination
MDA-MB-468 or SK-BR-3 cells seeded into 6-well plates
(1.5 × 105 cells/well) were allowed to grow for 24 hours
in the complete growth medium. Cells were subse-
quently treated with DMSO or perhexiline (10 μM) for
the indicated time. Cell lysates were prepared in 2 × SDS
sample buffer and subjected to Western blotting ana-
lysis. For ubiquitination assays, cells cultured and
treated as described were collected into glycerol lysis
buffer (50 mM Hepes, 250 mM NaCl, 0.5% NP40, 10%
glycerol, and 5 mM ethylenediamine tetraacetic acid).
Cell lysates were incubated with agarose-conjugated
anti-HER3 antibody overnight, washed three times
with the glycerol lysis buffer, and subjected to Western
blotting analysis.
Western blotting
The protein samples were subjected to SDS-PAGE
using 4 to 12% Novex™ Tris-Glycine Gels (Invitrogen,
Grand Island, NY, USA), transferred to nitrocellulose
membranes (Bio-Rad Laboratories, Hercules, CA, USA)
blocked with 5% nonfat milk powder in TBS-0.2%
Tween-20 for 30 minutes, followed by incubation
with primary antibodies and then horseradish peroxidase-
conjugated secondary antibodies (Amersham Biosciences,
Piscataway, NJ, USA). The ECL signals were detected
using SuperSignal substrate (Pierce Biotechnology,
Rockford, IL, USA) and quantified using ChemiDoc™
MP Imaging System (Bio-Rad Laboratories, Hercules,
CA, USA).Cell proliferation assay
The breast cancer cell lines MDA-MB-468, SK-BR-3,
AU565, and BT474 were used in the cell proliferation
assay. The cells were plated at 3,000 cells per well into
96-well plates and treated with compounds for 72 hours,
at which point the cell proliferation was measured using
the colorimetric MTS assay (Promega, Madison, WI,
USA). For the dose–response assays, the cells were
treated with perhexiline ranging from 0.5 to 10 μM.
To examine the combinational effect of perhexiline
and lapatinib, the cells were treated with perhexiline and
lapatinib alone or in combination. For the MDA-MB-
468 cells, the ratio of perhexiline to lapatinib was 1:1.
For the SK-BR-3, AU565, and BT474 cells, the ratio was
20:1. Experiments were performed in three replicates
and performed three times. Values were normalized as a
percentage of DMSO-treated cells. The Combination
Index (CI), which quantifies the degree of synergism in a
drug combination, was obtained using the method of
Chou and Martin in the software CompuSyn.
Testing the antitumor effect of perhexiline in vivo
All animal experiments were followed animal protocol
A294-11-11, which was reviewed and approved by the
Duke Institutional Animal Care and Use Committee.
MDA-MB-468 tumor cells (1 × 106/mouse) were injected
into the flank of SCID mice on day 0. On day 7, oral
gavage treatment with perhexiline (0, 400 mg/kg) was
initiated, and repeated for 5 days a week for 4 weeks.
Tumor diameter was measured every 3 to 4 days. Each
group consisted of five mice. Student’s t test was used to
analyze differences in tumor volumes at each perhexiline
concentration compared to vehicle control. Differences
at P <0.05 were considered statistically significant.
Results
Perhexiline promotes HER3 internalization and degradation
In contrast to the other members of the HER family of
receptor kinases, the HER3 receptor is not an active kin-
ase [1]. As a result, strategies targeting the kinase activ-
ity to develop small molecule therapeutics against HER3
similar to those employed to develop small molecules
against EGFR and HER2, are not applicable. To over-
come this hurdle, we developed an imaging-based high-
throughput screening strategy to search for small
molecules that promote HER3 internalization based on
the notion that receptor internalization often results in
loss of receptor function. Screening compound libraries
for their effects on membrane trafficking has proven to
be a highly rewarding strategy for identifying inhibi-
tors and activators of other enigmatic membrane re-
ceptors such as Frizzled and Smoothened [20,21].
Since endogenous HER3 receptors were expressed at
the plasma membrane, the cytosol, and the nucleus
Ren et al. Breast Cancer Research  (2015) 17:20 Page 4 of 11in MDA-MB-468 cells (Figure 1A, panel i), therefore in
this report, we utilized an YFP-tagged HER3ΔNLS2
(HER3ΔNLS2-YFP) expression construct, with the C-
terminal nuclear localization sequence (NLS2, a four
Arg-repeat) [22] removed in order to enhance membrane
localization. We found that this mutant receptor func-
tions similarly as wild-type (WT) HER3 in promoting
downstream signaling upon stimulation with neuregulin
β1 (NRGβ1) (Figure S1 in Additional file 1). Stable U2OS
cells were generated to express HER3ΔNLS2-YFP and
the receptors were predominantly expressed at the cellFigure 1 Identification of perhexiline as a novel agent that promotes
HER3ΔNLS2-YFP internalization. As a control to HER3ΔNLS2-YFP cellular dis
detected by immunofluorescence staining (i). U2OS cells stably expressing
HER3 internalization. Representative confocal images shown in panels (ii to
with DMSO, 10 μM perhexiline for 30 minutes and 4 hours, and 20 μM
intracellularly localized puncta of internalized HER3ΔNLS2-YFP receptors. (B) S
downregulation of endogenous HER3 receptors. Cell lysates prepared from SK
were analyzed for the expression of HER3, HER2, and EGFR. β-actin was use
expression following perhexiline treatment. Western blots shown in (C) were q
downregulation of endogenous HER3 in SK-BR-3 cells. Cells treated with 10 μM
HER2, and EGFR expression. (F) Quantification of HER3, HER2, EGFR protein exp
quantified by normalizing to β-actin. CPT-1, mitochondrial carnitine palmitoyltr
receptor; HER3, human epidermal growth factor receptor 3.surface basally (Figure 1A, panel ii), which is different
from endogenous HER3 expression throughout the cell
(Figure 1A, panel i). Using this cell line, we screened the
Prestwick Chemicals Library containing FDA and foreign
regulatory agency-approved drugs, and discovered per-
hexiline maleate (Figure 1B) induced HER3 receptor in-
ternalization (Figure 1A, panels iii and iv). Perhexiline is
a drug once used to treat angina (Figure 1B) [19]. The
mechanism responsible for its anti-angina activity is be-
lieved to result from inhibition of mitochondrial CPT-1.
To test whether inhibition of CPT-1 induced HER3HER3 internalization and degradation. (A) Perhexiline promotes
tribution, endogenous HER3 expression in MDA-MB-468 cells was
HER3ΔNLS2-YFP were used to screen for compounds that promote
v) were taken from cells expressing HER3ΔNLS2-YFP that were treated
CPT-1 inhibitor etomoxir for 4 hours, respectively. Arrows indicate
tructure of perhexiline maleate. (C) Perhexiline induces dose-dependent
-BR-3 cells treated with different concentrations of perhexiline for 8 hours
d as a loading control. (D) Quantification of HER3, HER2, EGFR protein
uantified by normalizing to β-actin. (E) Time course of perhexiline-induced
perhexiline for the indicated time were analyzed for endogenous HER3,
ression following perhexiline treatment. Western blots shown in (E) were
ansferase-1; DMSO, dimethyl sulfoxide; EGFR, epidermal growth factor
Ren et al. Breast Cancer Research  (2015) 17:20 Page 5 of 11receptor internalization, we tested the effect of another
CPT-1 inhibitor, etomoxir, on HER3 internalization. Our
result showed that etomoxir had no effect on HER3
localization (Figure 1A, panel v) suggesting perhexiline
operates through a mechanism independent of its ability
to inhibit CPT-1 [23].
Since receptor internalization often leads to degrad-
ation of receptor proteins, we next examined the effect
of perhexiline on the level of endogenous HER3 recep-
tors. As shown in Figure 1C and D, treating SK-BR-3
cells with increasing concentrations of perhexiline for
8 hours resulted in a dose-dependent downregulation of
HER3 protein. Interestingly, this effect is specific for
HER3 only as the expression of receptors in the same
family, including EGFR and HER2, were not affected by
perhexiline treatment (Figure 1C and D). Moreover, per-
hexiline (10 μM)-mediated downregulation of HER3 was
observed after 30 minutes and less than 10% of HER3
remained at the end of the 8-hour treatment (Figure 1E
and F). A similar effect of perhexiline on decreasing
HER3 expression was detected in triple-negative breast
cancer MDA-MB-468 cells that express EGFR and
HER3, but not HER2 (Figure S2 A-D in Additional
file 2). We also observed general cell toxicity when
cells were treated at 15 μM perhexiline. Perhexiline
also promotes the degradation of phosphorylated HER3,
an active form for HER3 signaling (Figure S2E in
Additional file 2) [9].
Perhexiline internalizes cell surface-expressed HER3 and
induces receptor ubiquitination
Our data showed that perhexiline stimulates HER3 in-
ternalization and degradation. To further prove that the
internalized receptor was from the cell surface, we
generated an N-terminal Flag-tagged HER3ΔNLS2
construct. Live cells expressing surface-localized Flag-
HER3ΔNLS2 receptors were labeled on ice with
fluorescence-conjugated Flag antibody to prevent internal-
ization of the receptor (Figure 2A, panel i). Raising the
temperature to 37°C caused a small amount of Flag-
HER3ΔNLS2 receptors to internalize as indicated by the
redistribution of labeled receptors to the cytoplasm in un-
treated or DMSO-treated cells (Figure 2A, panels ii
and iii). However, more internalized receptors were
observed in cells treated with perhexiline for 1 hour,
and these internalized receptors formed larger puncta
inside the cells (Figure 2A, panel iv).
We next determined if perhexiline induces HER3 deg-
radation by promoting ubiquitination of the receptor.
To this end, MDA-MB-468 cells were treated with
perhexiline over the time course of 2 hours, and en-
dogenous HER3 receptors were immunoprecipitated
from the cells. We found that perhexiline treatment was
accompanied by a rapid increase in the level of HER3ubiquitination (Figure 2B). Furthermore, perhexiline-
induced degradation of HER3 was partially rescued by
pretreating cells with MG132, a proteasome inhibitor, or
bafilomycin A1 (BFA1), a lysosome inhibitor (Figure 2C),
suggesting that perhexiline promotes both proteasome-
and lysosome-dependent degradation of ubiquitinated
HER3 receptors. Furthermore, despite the fact that en-
dogenous HER3 receptors were expressed at the plasma
membrane, the cytosol, and the nucleus in MDA-MB-
468 cells, treating cells with perhexiline resulted in the
redistribution of endogenous HER3 to the lysosomal
compartment. The internalized receptors were co-localized
with lysosomes in perhexiline-treated cells (Figure 2D).
Similarly, U2OS cells expressing HER3-ΔNLS2-YFP were
treated with DMSO (i to iii) or perhexiline (iv to vi) and
the internalized HER3-ΔNLS2-YFP receptors were co-
localized with lysosomes, confirming that perhexiline
induces HER3 degradation via the lysosome pathway
(Figure S3 in Additional file 3).
Perhexiline inhibits neuregulin-mediated signaling
activation and breast cancer cell proliferation
To determine the effect of perhexiline on HER3-
mediated oncogenic signaling in breast cancer cells,
serum-starved MDA-MB-468 cells were pretreated with
perhexiline and subsequently stimulated with NRGβ1.
As shown in Figure 3A, perhexiline treatment signifi-
cantly decreased NRGβ1-induced phosphorylation of
Akt and ERK. This inhibition of signaling coincided
with perhexiline-mediated downregulation of HER3
(Figure 3A). In addition, MTS assays were performed
to assess the effect of perhexiline on cell proliferation. Re-
sults showed that NRGβ1 treatment resulted in a 33.5%
increase in cell proliferation consistent with HER3’s
role in promoting tumor growth. Treating cells with
perhexiline decreased cell proliferation by 11.5% and
36.3% in serum-free and NRGβ1-containing medium, re-
spectively (Figure 3B).
To further determine the effect of perhexiline on
breast cancer cell proliferation, MDA-MB-468 and
SK-BR-3 cells were treated with different concentra-
tions of perhexiline for 72 hours in regular growth
medium. Perhexiline treatment effectively inhibited cell
proliferation in both cell lines with IC50 of 2.7 ± 0.07 and
4.8 ± 0.2 μM for MDA-MB-468 and SK-BR-3, respect-
ively (Figure 4A-B). These IC50 values were similar to
those needed to induce internalization and degradation
of HER3 receptors. Given upregulation of HER3 has been
found to be a major mechanism underlying drug resist-
ance to EGFR and HER2 tyrosine kinase inhibitors (for
example lapatinib, gefitinib, erlotinib) [12-14], we next
assessed the effect of perhexiline combined with lapati-
nib, an agent commonly used to treat HER2-positive
breast cancer. Treatment of MDA-MB-468 cells with
Figure 2 Perhexiline promotes cell surface-expressed Flag-HER3ΔNLS2 receptor internalization and the ubiquitination-mediated degradation
of HER3 receptors through lysosome and proteasome. (A) Cell surface-expressed Flag-HER3ΔNLS2 receptors are internalized upon perhexiline
treatment. HEK293 cells transfected with Flag-HER3ΔNLS2 were incubated with the anti-FLAG antibody on ice for 30 minutes (i) and subsequently
incubated at 37°C for 1 hour untreated (ii) or in the presence of DMSO or perhexiline (10 μM) (iii, iv). Cells were fixed and localization patterns of
Flag-HER3ΔNLS2 were visualized using confocal microscopy. Internalized Flag-HER3ΔNLS2 vesicles were shown as indicated by arrowheads in
DMSO-treated cells whereas arrows indicate large puncta of internalized receptors in perhexiline-treated cells. (B) Perhexiline induces HER3
ubiquitination. MDA-MB-468 cells were treated with perhexiline (10 μM) for the indicated time. The endogenous HER3 was immunoprecipitated
and the amount of ubiquitination and total HER3 were detected using the anti-ubiquitin and HER3 antibodies, respectively. (C) Perhexiline-induced
downregulation of HER3 is blocked by proteasome and lysosome inhibitors. MDA-MB-468 cells were treated with DMSO, MG132 (10 μM),
or BFA1 (30 nM) in the absence or presence of perhexiline (10 μM) for 8 hours. The endogenous HER3 was detected by the anti-HER3
antibody. (D) Perhexiline induces the redistribution of endogenous HER3 to the lysosome. MDA-MB-468 cells treated with DMSO (i to iii)
or 10 μM perhexiline (iv to vi) for 2 hours were fixed and analyzed using confocal microscopy. The localization of HER3 and the lysosome
was visualized using the anti-HER3 antibody (green) and LysoTracker (red), respectively. Co-localization of HER3 (green) with lysosome (visualized by
LysoTracker Red) was observed in perhexiline-treated cells as yellow puncta marked by arrows. DMSO, dimethyl sulfoxide; EGFR, epidermal growth
factor receptor; HER3, human epidermal growth factor receptor 3.
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phorylation and activation of HER3 and downstream
Akt signaling (Figure 4C). However, lapatinib treat-
ment after 36 hours led to the recovery of HER3 and
AKT phosphorylation, a result similar to the original
report describing lapatinib resistance mediated by HER3(Figure 4C) [12]. In contrast, the inhibition of HER3 and
downstream Akt signaling remained effective in cells
treated with a combination of 5 μM perhexiline and
100 nM lapatinib, suggesting that perhexiline can poten-
tially be used to prevent the resistance to HER family
tyrosine kinase inhibitors (Figure 4C).
Figure 3 Perhexiline treatment inhibits neuregulin-mediated activation of downstream signaling and cell proliferation. (A) MDA-MB-468
cells were cultured in the absence or presence of perhexiline (10 μM) for 6 hours, and subsequently stimulated with DMSO or NRGβ1 (10 ng/ml)
for 10 minutes. Cell lysates were analyzed for the phosphorylation of HER3 (Tyr1289), Akt and ERK1/2 as well as total HER3 expression. (B) Perhexiline
inhibits NRGβ1-induced cell growth. MB-MDA-468 cells were treated for 72 hours with vehicle (0.2% BSA in PBS) or NRGβ1 (10 ng/ml) in the
presence of DMSO or perhexiline (2 μm). Cell growth was measured using the MTS assay. NRGβ1 treatment resulted in 33.5% increase of cell
proliferation. Perhexiline inhibits 11.5% cells in vehicle media and 36.3% cell growth in NRGβ1 media. Data are presented as the mean ± SEM
(n = 3). The statistical significance between DMSO control and perhexiline treatment in vehicle media or NRGβ1 media was analyzed by a two-tailed
Student’s t test, (with *P <0.05 defined as significant compared to the control group with only NRGβ1 treatment). BSA, bovine serum albumin; DMSO,
dimethyl sulfoxide; ERK, extracellular signal-regulated protein kinase; HER3, human epidermal growth factor receptor 3; NRGβ1, neuregulin β1; PBS,
phosphate-buffered saline; SEM, standard error of the mean.
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eration was then studied in MDA-MB-468 and SK-BR-3
cells. Combination of perhexiline and lapatinib at each
of the four indicated doses (1 to 4 μM) resulted in a
more pronounced inhibition in cell proliferation com-
pared to cells treated with perhexiline or lapatinib alone
in MDA-MB-468 cells (Figure 4D). Statistical analysis of
the combination dose effect [24] demonstrated that
combinational index (CI) values were less than 1, indi-
cating perhexiline synergistically enhances the antitumor
effect of lapatinib.
The combinational effects of perhexiline and lapatinib
on SK-BR-3 cells also resulted in similar inhibition in cell
proliferation. The CI values of the 75% and 90% effective
doses (ED75, ED90) were less than 1. The CI value for one
experimental point was below 1 (Figure 4E).
We chose two additional breast cancer cell lines,
AU565 and BT474, to test the inhibitory effect of
perhexiline on cell proliferation, both alone and in com-
bination with lapatinib. Perhexiline inhibited cell prolif-
eration in both cell lines with IC50 of 6.1 ± 0.07 and
4.0 ± 0.04 μM, respectively (Figure S4A, C in Additional
file 4). Perhexiline also synergistically enhanced the anti-
proliferative effect of lapatinib. For example, in AU565
cells, the CI values at the ED75, ED90 and ED95 as well
as at all four experimental combinations were less than 1
(Figure S4B in Additional file 4), suggesting robust syner-
gistic effect. In BT474 cells, however, the CI values were
less than 1 at the ED75 and ED90 doses and in only twoout of four experimental combinations (Figure S4D in
Additional file 4), suggesting the synergy of the combin-
ation in BT474 cell line was less robust. These data indi-
cate that perhexiline inhibits breast cancer cells growth
and its inhibitory effect is synergized with lapatinib.
Perhexiline inhibits tumor growth in vivo
The antitumor effect of perhexiline was then studied
in vivo. Triple-negative MDA-MB-468 cells were inocu-
lated subcutaneously into SCID mice and 7 days later,
oral gavage perhexiline was initiated and dosed five
times a week. As shown in Figure 5A, perhexiline signifi-
cantly inhibited the growth of MDA-MB-468 tumors.
During the course of the treatment with perhexiline, no
obvious side effects such as body weight loss were ob-
served in the treated mice (Figure 5B). In addition,
tumor masses were excised, homogenized, and immune-
blotted for the expression of phosphorylated HER3.
Perhexiline-treated tumors showed significantly decreased
levels of phosphorylated HER3 compared to control tu-
mors (Figure 5C-D). Taken together, these results indi-
cated that perhexiline inhibits tumor growth and HER3
signaling in vivo.
Discussion
Collectively, we report the development of a novel ap-
proach to inhibit HER3 signaling via the application of
an imaging-based HER3 internalization assay to identify
small molecule inhibitors of HER3-mediated signaling.
Figure 4 Perhexiline inhibits breast cancer cell proliferation and functions synergistically with lapatinib. (A-B) MDA-MB-468 (A) and
SK-BR-3 (B) cells were treated with different concentrations of perhexiline for 72 hours, and cell viability was measured using the MTS assay. Each
experimental point was performed in triplicate, and results represent mean ± SEM of three independent experiments. (C) The synergistic effect of
perhexiline and lapatinib on inhibiting HER3-mediated Akt signaling. MDA-MB 468 cells treated with 5 μM perhexiline alone or in combination
with 100 nM lapatinib for 2 or 36 hours. Cell lysates were analyzed for the phosphorylation status of endogenous HER3 and Akt as well as total
HER3 and Akt expression. (D-E) Perhexiline and lapatinib synergistically inhibit MDA-MB-468 (D) and SK-BR-3 (E) cell growth. Cells were treated
with increasing concentrations of perhexiline and lapatinib alone or in combination for 72 hours. MTS assays were performed to measure cell
viability. Values are expressed as a percentage of DMSO-treated cells. Results are presented as the mean ± SEM. Combinational index (CI) quantifies
the degree of synergism in a drug combination. CI is obtained using the method of Chou and Martin in the software CompuSyn. CI <1 indicates
drug synergy. ED50, ED75, ED90 and ED95 are the effective doses at which 50%, 75%, 90% and 95% cells are killed, respectively. DMSO, dimethyl
sulfoxide; HER3, human epidermal growth factor receptor 3; SEM, standard error of the mean.
Ren et al. Breast Cancer Research  (2015) 17:20 Page 8 of 11This robust assay allows high-throughput screening to
discover both small molecules and antibodies targeting
HER3. Moreover, it overcomes the barrier of developing
HER3-targeted small molecule therapies imposed by the
fact that HER3 lacks active kinase activity. To our know-
ledge, perhexiline is the first small molecule identified
that promotes selective HER3 degradation and inhibition
of HER3-mediated signaling by inducing receptor intern-
alization. Consistent with this mechanism, perhexilinealso inhibits breast cancer cell proliferation in vitro and
tumor growth in vivo and synergizes with lapatinib to in-
hibit breast cancer cell growth.
Increasing evidence has identified HER3 as one of the
most potent oncogenic factors in promoting breast can-
cer tumorigenesis [5]. In animal models of breast cancer
driven by HER2, HER3 expression and phosphorylation
are upregulated [6,7]. In addition, overexpression of
HER3 has been shown to significantly enhance the
Figure 5 Perhexiline inhibits the tumorigenesis of MDA-MB-468 cells in NOD/SCID mice. (A) MDA-MB-468 cells (1 × 106/mouse) were
injected to the flank of SCID mice on day 0. On day 7, oral gavage treatment with perhexiline (0, 400 mg/kg) was initiated, and repeated for 5 days
a week for 4 weeks. Tumor diameter was measured every 3 to 4 days. Each group consisted of five mice. Date represent mean ± SEM (n = 5, *P <0.05
by a two-tailed Student’s t test). (B) The body weight was measured at the same time of tumor measurement. Each group consisted of five mice.
Data represent mean ± SEM (n = 5, *P <0.05 by a two-tailed Student’s t test). (C) Tumor samples were collected from all five mice in the control and
perhexiline-treated group and processed for Western blotting analysis. The level of phospho-HER3 was detected using the phospho-Tyr1289 antibody.
β-actin was used as a loading control. (D) Quantitative representation of p-HER3 levels. Western blots shown in (C) were quantified by normalizing to
β-actin. Data represent mean ± SEM (n = 5, *P <0.05 by a two-tailed Student’s t test compared to the control group). HER3, human epidermal growth
factor receptor 3; SEM, standard error of the mean.
Ren et al. Breast Cancer Research  (2015) 17:20 Page 9 of 11invasiveness of breast cancer cells. Specifically, HER3
promotes invasion and metastasis through its ability
to activate the PI3K pathway [9]. The clinical impact
of HER3 is indicated by the observation that increased
HER3 expression [10] and the detection HER2/HER3
dimers [11] have prognostic significance in breast
cancer.
With the exception of HER3, the HER family of mem-
brane receptors all have intrinsic tyrosine kinase activity.
This kinase activity enabled successful small molecule
drug discovery approaches by targeting the kinase en-
zyme activity with inhibitors that bind in the ATP active
site. Given HER3 is not an active kinase enzyme, small
molecule approaches to inhibit its signaling activity was
not considered feasible. Pertuzumab, a monoclonal anti-
body that blocks dimerization of HER2 and HER3 recep-
tors, was approved by the FDA for concurrent use in
combination with trastuzumab and docetaxel [25]. It
provides a proof of concept of targeting HER3 as an ef-
fective therapy. However monoclonal antibodies against
HER3 have not demonstrated clinical benefits as single
agents based on published data as summarized in recent
reviews [26,27]. Other approaches targeting HER3 are
demanded in clinic.Perhexiline is an anti-angina drug with the inhibitory
properties against the enzyme mitochondrial CPT-1.
The plasma concentration of perhexiline in humans
within its therapeutic range is about 2 μM [28]. Distribu-
tion studies indicate that perhexiline is preferentially dis-
tributed in tissues. For example in heart, the perhexiline
concentration is at least 10-fold higher than in serum
[19,29]. The distribution of perhexiline into tumors ver-
sus other tissues is unknown; the concentration of per-
hexiline in tumors needs to be determined.
The anticancer properties of perhexiline are not well
known. It has been reported that perhexiline has an ef-
fect on adriamycin-resistant human breast cancer cells.
Simultaneous exposure to tamoxifen or perhexiline de-
creased resistance to adriamycin in a clonogenic assay
by an undefined mechanism [30]. Here, we report the
anti-breast cancer properties of perhexiline through
HER3 degradation and HER3-mediated signaling inhib-
ition. The synergistic inhibitory effect of perhexiline
with lapatinib on tumor growth may provide immediate
therapeutic benefits for breast cancer patients with drug
resistance and metastasis.
In summary, our findings represent a proof of principle
by demonstrating the ability of a small molecule to
Ren et al. Breast Cancer Research  (2015) 17:20 Page 10 of 11selectively downregulate HER3 but not other epidermal
growth factor receptor (EGFR) family members and inhibit
downstream signaling in breast cancer cells and tumors.
As a clinically used drug, perhexiline may be administrated
alone, or in combination with other existing therapies such
as lapatinib, to overcome drug resistance and metastasis in
cancer treatment. Perhexiline is a first-in-class small mol-
ecule that targets HER3. Optimization of its pharmaceut-
ical properties could provide improved derivatives with
greater benefit to breast cancer patients. Clinical evaluation
of perhexiline and its improved derivatives may directly
lead to a new therapy to treat breast cancer and other
HER3-dependent cancers.Conclusions
Ablating HER3 offers the potential to decrease mortality
in breast cancer in patients. Using a novel image-based
high-throughput screening assay, we discovered the
small molecule drug perhexiline, once used to treat an-
gina, ablates HER3 by promoting HER3 internalization
and degradation. This is the first demonstration that
HER3 can be targeted with small molecule by elimin-
ating it from the cell membrane. Consistent with this
mechanism, perhexiline inhibits HER3-mediated sig-
naling as well as the growth of breast cancer cells
in vitro and in vivo. Our approach overcomes a barrier
to develop small molecule therapies targeting HER3.
HER3 ablation modulators represent an innovative
therapeutic approach to improve survival in breast can-
cer patients.Additional files
Additional file 1: Figure S1. The HER3ΔNLS2-YFP receptor functions
similarly as the wild-type HER3-YFP receptor. U2OS cells were transiently
transfected with vector, HER3-YFP, or HER3ΔNLS2-YFP expression plasmids.
Cells were treated with NRGβ1 for 0 to 30 minutes as indicated, and cell
lysates were analyzed for HER3 expression and Akt phosphorylation.
Additional file 2: Figure S2. Perhexiline treatment induces
downregulation of endogenous HER3 receptors in MDA-MB-468 cells.
(A) Time course of perhexiline-induced downregulation of endogenous
HER3. Cells treated with 10 μM perhexiline for the indicated time were
analyzed for endogenous HER3 and EGFR expression. β-actin was used
as a loading control. (B) Quantification of HER3 and EGFR protein expression
following perhexiline treatment. Western blots shown in (A) were quantified
by normalizing to β-actin. (C) Dose-dependent effect of perhexiline
on HER3 expression. Cell lysates prepared from cells treated with
different concentrations of perhexiline for 8 hours were analyzed for
the expression of HER3 and EGFR. (D) Quantification of HER3 and EGFR
protein expression following perhexiline treatment. Western blots shown
in (C) were quantified by normalizing to β-actin. (E) Dose-dependent
effect of perhexiline on HER3 phosphorylation. Cell lysates prepared from
cells treated with different concentrations of perhexiline for 6 hours were
analyzed for the phosphorylation of HER3 at Tyr1289 site.
Additional file 3: Figure S3. Perhexiline induces trafficking of HER3
to lysosome. U2OS cells expressing HER3-ΔNLS2-YFP were treated
with DMSO (i to iii) or perhexiline (iv to vi) and co-localization of
HER3ΔNLS2-YFP (green) with lysosome (red) was indicated by arrows.Additional file 4: Figure S4. Perhexiline inhibits breast cancer cell
proliferation and functions synergistically with lapatinib. (A and C) The
antiproliferative effects of perhexiline on AU565 (A) and BT474 (C) breast
cancer cells. Cells were treated with different concentrations of perhexiline
for 72 hours, and cell viability was measured using the MTS assay. Results
represent mean ± SEM of three independent experiments. (B and D) The
synergistic effect of perhexiline and lapatinib on inhibiting proliferation
of AU565 (B) and BT474 (D) cells. Cells were treated with increasing
concentrations of perhexiline and lapatinib alone or in combination for
72 hours. MTS assays were performed to measure cell viability. Results are
presented as the mean ± SEM. Combinational Index (CI) quantifies the
degree of synergism in a drug combination. CI is obtained using the
method of Chou and Martin in the software CompuSyn. CI <1 indicates
drug synergy. ED50, ED75, ED90 and ED95 are the effective doses at which
50%, 75%, 90% and 95% cells are killed, respectively.
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